SCHEMBL7283121

SCHEMBL7283121

COc1cc(CO)cc(F)c1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.48
HTR2C P28335 2/20 0.48
HTR2B P41595 2/20 0.48
PTGS2 P35354 1/20 0.48
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 2/20 0.44
CYP3A4 P08684 1/20 0.42
TUBB1 Q9H4B7 4/20 0.41
TUBB4A P04350 3/20 0.41
TUBB P07437 3/20 0.41
TUBA3C P0DPH7 3/20 0.41
TUBA1B P68363 3/20 0.41
TUBA4A P68366 3/20 0.41
TUBB4B P68371 3/20 0.41
TUBB3 Q13509 3/20 0.41
TUBB2A Q13885 3/20 0.41
TUBB8 Q3ZCM7 3/20 0.41
TUBA3E Q6PEY2 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764427 0.88 MAPT (0.50) HTR2AHTR2CHTR2BPTGS2HSD17B10
SCHEMBL1122521 0.86 PTGS2 (0.64) HTR2AHTR2CHTR2BPTGS2HSD17B10
SCHEMBL19806073 0.85 HTR2A (0.48) HTR2AHTR2CHTR2BPTGS2MAPT
SCHEMBL29976346 0.85 HTR2A (0.48) HTR2AHTR2CHTR2BPTGS2MAPT
SCHEMBL17610643 0.82 CYP4F2 (0.42) HTR2AHTR2CHTR2BHSD17B10ALOX15
SCHEMBL22817375 0.81 CYP4F2 (0.41) HTR2AHTR2CHTR2BHSD17B10ALOX15
SCHEMBL17655662 0.80 PTGS2 (0.52) HTR2AHTR2CHTR2BPTGS2HSD17B10
SCHEMBL1055709 0.80 MGAM (0.45) HSD17B10ALDH1A1
SCHEMBL31063117 0.79 HSD17B10 (0.49) HSD17B10ALOX15TSHRMAPTCYP4F2
SCHEMBL16411031 0.79 THRB (0.44) HTR2AHTR2CPTGS2MAPTCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124173-A1 THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-20250304533-A1 THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-10-02 US disclosed
US-12410128-B1 Therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2025-09-09 US disclosed
WO-2025101939-A1 THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2025-05-15 WO disclosed
US-4803225-A Dihydroxy-phenethylamino compounds useful as pharmaceuticals FISONS, PLC (GB) 1989-02-07 US disclosed
US-4720586-A Substituted 3,4-dihydroxy-phenylethylamino compounds FISONS, PLC (GB) 1988-01-19 US disclosed
EP-0142283-A2 Phenylethylamines, process for their preparation and compositions containing them FISONS plc (GB) 1985-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304533-A1 THERAPEUTIC ALKALOID COMPOUNDS HTR3B, MTNR1B, PNMT HTR2A 65/4885HTR2C 107/4885HTR2B 80/4885
US-20260124173-A1 THERAPEUTIC ALKALOID COMPOUNDS ADRA1B, HTR1B, ADRB1 HTR2A 38/4885HTR2C 37/4885HTR2B 9/4885
US-12410128-B1 Therapeutic alkaloid compounds HTR3B, MTNR1B, PNMT HTR2A 65/4885HTR2C 107/4885HTR2B 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.